| 1 minute

Scottish Enterprise supports TC BioPharm tie up with Japanese medical giant

Edinburgh-based medical research company TC BioPharm has formed a strategic collaboration with Japanese multinational Nipro Corporation to develop a new immunotherapy drug aimed at range of cancers, boosted by £2.7m of Scottish Enterprise funding.

The product will use TCB’s “safe CAR-T platform”, which is based on the unique properties of modified gamma delta T cells to selectively target cancer whilst leaving healthy cells untouched. CAR-Ts is the term for chimeric antigen receptors, immunotherapies that graft an arbitrary specificity onto an immune effector cell.

To read the full article, click here.
Back to News

Do you have news for the Scottish Life Sciences Community?

Submit Your Own News
Top
Notice: ob_end_flush(): Failed to send buffer of zlib output compression (0) in /home/lifescsc/public_html/wp-includes/functions.php on line 5420